SCHEMBL2014384

SCHEMBL2014384

O=[N+]([O-])c1cc(F)c(CO)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HIF1A Q16665 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TTR P02766 1/20 0.42
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
PMP22 Q01453 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GPR35 Q9HC97 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3832323 0.81 HTT (0.42) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL23388197 0.79 CYP19A1 (0.43) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL6607355 0.79 CYP1A2 (0.51) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL3832070 0.79 HTT (0.43) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL20718865 0.78 TAAR1 (0.50) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL8744302 0.77 ALDH1A1 (0.53) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL29739378 0.76 HTT (0.44) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL29177356 0.76 HTT (0.44) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL1137222 0.76 ALDH1A1 (0.57) CYP19A1ALDH1A1MEN1KMT2AHIF1A
SCHEMBL10917076 0.75 ALDH1A1 (0.59) CYP19A1ALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4237008-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF Elucida Oncology, Inc. (US) 2023-09-06 EP disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 US disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 US disclosed
WO-2022093800-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 WO disclosed
US-20120322768-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS QUEEN MARY & WESTFIELD COLLEGE (GB) 2012-12-20 US disclosed
WO-2011066416-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PROTOZOAN INFECTIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP CYP19A1 3930/4885ALDH1A1 1060/4885MEN1 2314/4885
US-20120322768-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS PHOSPHO1, CYCS, DPM1 CYP19A1 1638/4885ALDH1A1 2072/4885MEN1 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.